Search

ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

Press release

… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …

april 25, 2016
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Press release

Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th

augustus 15, 2018
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

Press release

… ProQR Announces Positive Interim Results from Phase 1/2 … & CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … executive vice president of research and development of ProQR. “We observed a clinically meaningful improvement in …

september 05, 2018
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

Press release

… ProQR Therapeutics Teams Up with the Foundation Fighting … and CAMBRIDGE, Mass, Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … for IRDs. Daniel de Boer, Chief Executive Officer of ProQR, said, “We are honored to be the first industry partner …

februari 06, 2020
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Press release

The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018

juni 12, 2018
ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

Press release

… ProQR annonce des résultats intermédiaires positifs pour un … Massachusetts, 05 sept. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), une entreprise qui … vice-président exécutif recherche et développement de ProQR. « Nous avons observé une amélioration cliniquement …

september 05, 2018